Trialbee and TriNetX Partner
Trialbee, a technology provider in patient matching and engagement, is partnering with TriNetX, a global real-world health research network comprised of >170M patients across 23 countries to support data-driven digital solutions.
“This partnership will significantly widen Trialbee’s service offerings to drive patient recruitment and retention,” said Lollo Eriksson, CEO of Trialbee. “This is a great opportunity to leverage both organizations capabilities to develop new services in order to optimize clinical trials to empower patients with clinical trials as a care option. TriNetX is the market leader in leveraging real world data for the applications of clinical trial design, feasibility and site selection, and we look forward to embarking on this journey together.”
Trialbee develops innovative software to reduce clinical trial recruitment timelines and enhance the patient engagement experience, and TriNetX optimizes clinical research and enables discoveries through the generation of real-world evidence (RWE). TriNetX’s access to patients through its global healthcare organizations (HCO) partners as well as through publicly available sources, and Trialbee’s expertise in patient recruitment and digital outreach represent a multi-pronged approach to identify, engage, and drive patients to clinical trials, improving efficiency and time-to-market.
With TriNetX’s real-time access to a large data repository, patient populations, and network of HCOs, and Trialbee’s seamless patient recruitment experience, the two companies will harness the power of RWE and real-time analytics to support customers with their end goals of protocol design, site selection, patient recruitment and retention.
“Our collaboration with Trialbee further enhances our healthcare organizations’ capabilities to streamline patient identification and recruitment. We see this partnership as a complementary effort to our digital developments around protocol design, site identification and access to patients.” said Maulik Mehta, Sr. VP Corporate Development. “Together, TriNetX and Trialbee will further enable clinical research as an alternative care option to patients.”
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
